<?xml version="1.0" encoding="UTF-8"?>
<ref id="B47-viruses-12-00021">
 <label>47.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Papanicolaou</surname>
    <given-names>G.A.</given-names>
   </name>
   <name>
    <surname>Silveira</surname>
    <given-names>F.P.</given-names>
   </name>
   <name>
    <surname>Langston</surname>
    <given-names>A.A.</given-names>
   </name>
   <name>
    <surname>Pereira</surname>
    <given-names>M.R.</given-names>
   </name>
   <name>
    <surname>Avery</surname>
    <given-names>R.K.</given-names>
   </name>
   <name>
    <surname>Uknis</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Wijatyk</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Boeckh</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Marty</surname>
    <given-names>F.M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, phase 2 Study</article-title>
  <source>Clin. Infect. Dis.</source>
  <year>2019</year>
  <volume>68</volume>
  <fpage>1255</fpage>
  <lpage>1264</lpage>
  <pub-id pub-id-type="doi">10.1093/cid/ciy706</pub-id>
  <pub-id pub-id-type="pmid">30329038</pub-id>
 </element-citation>
</ref>
